RxDoctor Payments Data

Uzochukwu Emukah

Psychiatric/Mental Health · Sugar Land, TXNPI 1124612320

Payments from drug & device makers

$7,226in general payments, 2019–2025

Across 140 payments — averaging $51.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • AbbVie$880
  • Axsome Therapeutics, Inc.$794
  • Teva Pharmaceuticals USA, Inc.$712
  • Neurocrine Biosciences, Inc.$606
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$7,226100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,226 in reported general payments places this provider in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$12,513
Medicare patients
22
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate11$23,337
Aripiprazole29$5,251
Quetiapine Fumarate81$1,754
Escitalopram Oxalate64$1,228
Duloxetine Hcl55$1,209
Buspirone Hcl44$923
Ziprasidone Hcl12$913
Bupropion XlBupropion Hcl45$817
Trazodone Hcl85$807
Oxcarbazepine12$575
Sertraline Hcl71$524
Hydroxyzine Hcl19$439
Mirtazapine35$374
Divalproex Sodium ErDivalproex Sodium15$240
Lamotrigine41$231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$105$23,33711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →